After 14 years of debate, the same association recommended the use of t-PA within the first 3 h of onset (strong recommendation, high level of evidence) but recommended against its use beyond 3 h, except in specialized stroke centers with advanced imaging capabilities or as part of a research protocol, despite increasing evidence supporting its effectiveness [22]. This evidence concerns the gene PLAT and stroke disorder.